Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Century Therapeutics (IPSC) Net Income (2022 - 2025)

Century Therapeutics (IPSC) has disclosed Net Income for 4 consecutive years, with -$19.2 million as the latest value for Q4 2025.

  • Quarterly Net Income fell 121.69% to -$19.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$9.6 million through Dec 2025, down 439.56% year-over-year, with the annual reading at -$9.7 million for FY2025, 440.78% down from the prior year.
  • Net Income for Q4 2025 was -$19.2 million at Century Therapeutics, up from -$34.4 million in the prior quarter.
  • The five-year high for Net Income was $88.7 million in Q4 2024, with the low at -$39.4 million in Q4 2023.
  • Average Net Income over 4 years is -$17.4 million, with a median of -$31.2 million recorded in 2023.
  • Peak annual rise in Net Income hit 372.82% in 2025, while the deepest fall reached 121.69% in 2025.
  • Over 4 years, Net Income stood at -$31.7 million in 2022, then decreased by 24.37% to -$39.4 million in 2023, then surged by 325.16% to $88.7 million in 2024, then tumbled by 121.69% to -$19.2 million in 2025.
  • According to Business Quant data, Net Income over the past three periods came in at -$19.2 million, -$34.4 million, and -$32.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.